Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations
- PMID: 31782610
- PMCID: PMC11896544
- DOI: 10.1002/kjm2.12147
Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations
Abstract
Increasing evidence has indicated the intimate relationship between the gastrointestinal tract and respiratory tract. The microbial ecosystem has been confirmed to share key conceptual features with gut-lung microbiome disorder and dysregulation during chronic obstructive pulmonary disease (COPD) exacerbations. However, the dynamic changes of the gut-lung microbiome during COPD exacerbations and its potential role in disease etiology remain poorly understood. The present study investigated the dynamic changes of gut and lung microorganisms during acute exacerbation of chronic obstructive pulmonary disease (AECOPD). A longitudinal 16S ribosomal DNA survey of the gut and lung microbiome was completed on 90 feces and sputum samples collected from 15 subjects with AECOPD at three visits, which were defined as exacerbation, seven-day stable state. The present analysis revealed a dynamic gut-lung microbiota, where changes appeared to be associated with exacerbation events indicative of specific exacerbation phenotypes. Antibiotic and steroid treatments appeared to have differential effects on the gut-lung microbiome, and the microbiome was associated with disease progression, but not with severity. The abundance and diversity of the microbiome was strongly influenced by the disease progression and therapy. Using culture-independent methods to impact the gut and lung microbiota on AECOPD may be the key to understanding the interactions between the gut and lung, highlighting its potential as a biomarker, and possibly a target for future respiratory therapeutics.
Keywords: acute exacerbations of chronic obstructive pulmonary disease; dynamic changes; gut-lung; microbiome.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.
Conflict of interest statement
All authors declare no conflict of interest.
Figures





Similar articles
-
Lung microbiome dynamics in COPD exacerbations.Eur Respir J. 2016 Apr;47(4):1082-92. doi: 10.1183/13993003.01406-2015. Epub 2016 Feb 25. Eur Respir J. 2016. PMID: 26917613
-
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31. Thorax. 2018. PMID: 29386298 Free PMC article.
-
Variations in fecal microbial profiles of acute exacerbations and stable chronic obstructive pulmonary disease.Life Sci. 2021 Jan 15;265:118738. doi: 10.1016/j.lfs.2020.118738. Epub 2020 Nov 10. Life Sci. 2021. PMID: 33181175
-
COPD and the microbiome.Respirology. 2016 May;21(4):590-9. doi: 10.1111/resp.12732. Epub 2016 Jan 27. Respirology. 2016. PMID: 26852737 Review.
-
Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease.Chin Med J (Engl). 2017 Sep 5;130(17):2107-2111. doi: 10.4103/0366-6999.211452. Chin Med J (Engl). 2017. PMID: 28741603 Free PMC article. Review.
Cited by
-
Exploring the Change of Host and Microorganism in Chronic Obstructive Pulmonary Disease Patients Based on Metagenomic and Metatranscriptomic Sequencing.Front Microbiol. 2022 Mar 16;13:818281. doi: 10.3389/fmicb.2022.818281. eCollection 2022. Front Microbiol. 2022. PMID: 35369515 Free PMC article.
-
Herbal medicine in the treatment of COVID-19 based on the gut-lung axis.Acupunct Herb Med. 2022 Sep;2(3):172-183. doi: 10.1097/HM9.0000000000000038. Epub 2022 Dec 8. Acupunct Herb Med. 2022. PMID: 37808350 Free PMC article. Review.
-
Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.Front Microbiol. 2024 Oct 16;15:1487393. doi: 10.3389/fmicb.2024.1487393. eCollection 2024. Front Microbiol. 2024. PMID: 39483760 Free PMC article.
-
Lower gastrointestinal tract dysbiosis in persistent critical illness: a systematic review.J Med Microbiol. 2024 Oct;73(10):001888. doi: 10.1099/jmm.0.001888. J Med Microbiol. 2024. PMID: 39383061
-
7-Ethoxycoumarin rescued Caenorhabditis elegans from infection of COPD derived clinical isolate Pseudomonas aeruginosa through virulence and biofilm inhibition via targeting Rhl and Pqs quorum sensing systems.World J Microbiol Biotechnol. 2023 May 26;39(8):208. doi: 10.1007/s11274-023-03655-8. World J Microbiol Biotechnol. 2023. PMID: 37231227
References
-
- Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. - PubMed
-
- Rodriguez‐Roisin R, Bartolome SD, Huchon G, Krowka MJ. Inflammatory bowel diseases, chronic liver diseases and the lung. Eur Respir J. 2016;47:638–650. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical